OsteoGeneX is Developing a Sclerostin Inhibitor Too

Wnt modulators in the biotech pipeline.

Rey JP, Ellies DL
Dev. Dyn. Jan 2010
PMID: 20014100 | Free Full Text


A more favorable approach to the modulation of the Wnt pathway has been to focus on extracellular mediators of the pathway. Where, Amgen is the first in class to develop a biologic therapeutic against Sclerostin (Human Clinical Phase II). Nuvelo is following Amgen with biologics against LRP5, Dkk1, and R-Spondin (Discovery). Second in class for Sclerostin blocking antibodies will be Novartis and Eli Lilly (Preclinical). Fibrogen, who is taking a different approach, has developed a biologic against CCN family member CTGF (Preclinical). As for small molecules, OsteoGeneX is first in class to develop a Sclerostin small molecule inhibitor, currently in preclinical and lead optimization. Alternatively to Sclerostin, Galapagos is developing small molecule leads against LRP5 in a partnership with Eli-Lilly (Discovery).

Leave a Reply

Your email address will not be published.